Brian Yang
Managing Editor
Brian is in charge of overall China coverage within the APAC pharma news team. A veteran journalist, he has written extensively on R&D, regulatory, market access and business issues. Brian has led a team of writers providing industry-leading coverage in the second-largest health care market.
Latest From Brian Yang
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.
China Biotech Hopes Innovation Wins The Day As Legislative Attacks In US Congress Increase
The latest development shows that BIOSECURE Act is gaining momentum in the US Congress and off Capitol Hill. In the meanwhile, the Chinese biotech sector embraces uncertainty but hopes that common interests in health innovation will prevail in the end.
US Senate Advances BIOSECURE Legislation As China Biotech Security Heats Up
The US Senate moves closer to new legislation that would restrict Chinese "biotech companies of concern” from operating in the US, potentially causing broad and far-reaching impact.
China Lowers GDP Target As VBP And Corruption In Focus At 'Two Sessions'
Amid slack domestic consumption and declining overseas demand, 2024 may be the start of a multi-year slowing in growth for the world’s second-largest economy. In the health sector, volume-based procurement continues to expand while the focus of anti-corruption campaigns appears to be changing.
China Lowers GDP Target As VBP And Corruption In Focus At 'Two Sessions'
Amid slack domestic consumption and declining overseas demand, 2024 may be the start of a multi-year slowing in growth for the world’s second-largest economy. In the health sector, volume-based procurement continues to expand while the focus of anti-corruption campaigns appears to be changing.
US Toning Down China CDMO Tension But New Restrictions Emerge
The latest developments in a US Congressional draft bill to curb Chinese biotech operations in the US is separating contract manufacturing and research from gene sequencing service providers, which may give China's major contract players reasons to breathe easy.